HRS-1893
HRS-1893 Out-Licensed by Hengrui, Enters Myosin Inhibitor Race with Aficamten & Mavacamten
Hengrui Pharma’s HRS-1893, a selective cardiac myosin inhibitor, enters the global race alongside aficamten (CK-274) and mavacamten (Camzyos) via a Braveheart Bio licensing deal. ESC 2025 Phase I data show safety, PK, and marked LVOT gradient reduction in oHCM; Phase III (NCT07021976) is ongoing.